Effects of SGI-1776 on MCL malignant lymphocytes and normal PBMCs. Effects of SGI-1776 on phospho–c-Myc (Ser62) and total c-Myc, Mcl-1, cyclin D1 and phospho–4E-BP1 (Thr37/46), and total 4E-BP1 protein expressions in MCL malignant lymphocytes (A) and normal PBMCs from MCL patients and apparently healthy donors (C). Primary patient cells were treated with 0.1, 1, 3, 5, or 10μM, and normal PBMCs were treated with 1, 3, or 10μM SGI-1776 for 24 hours, and then cell lysates were analyzed via immunoblot. Untreated Mino cells were positive control. Apoptosis levels measured by annexin V and PI positivity is marked under each lane of the immunoblot in each primary sample. Effects of SGI-1776 on MCL1 mRNA expression levels in primary MCL malignant lymphocytes (B) and normal PBMCs from MCL patients and healthy donors (D). Primary PBMCs were treated with SGI-1776 using concentrations mentioned in this legend; RNA was isolated and analyzed using real-time RT-PCR.